Clinical Study

Randomized Phase III Study Of Sorafenib Versus Stereotatic Body Radiation Therapy Followed By Sorafenib In Hepatocellular Carcinoma

Posted Date: May 15, 2019

  • Investigator: Kevin Redmond
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to compare the effects of sorafenib alone (the present standard of care treatment) with SBRT followed by sorafenib on you and your liver cancer to find out which is better. In this study, you will get either SBRT followed by sorafenib or the sorafenib alone.

Criteria:

To Be Eligible For This Study, Patients Must Have Primary Liver Cancer, Referred To As Hepatocellula

Keywords:

Cancer, R1112, Gastrointestinal, Radiation, Liver Cancer

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.